TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

TAVR, SAVR linked to comparable long-term outcomes, new meta-analysis confirms
Researchers tracked data from more than 7,500 patients, sharing their findings at EuroPCR 2024 in Paris and in JSCAI.
Updated balloon-expandable TAVR valve from Edwards outperforming its predecessors
The fifth-generation valve is associated with improved hemodynamic data and a reduced rate of paravalvular leak, according to new research published in JACC: Cardiovascular Interventions and EuroIntervention.
Moderate aortic stenosis linked to heightened risk of death—should TAVR, surgery be considered?
Researchers tracked data from more than 400,000 patients for a new meta-analysis, presenting their findings in the Journal of the American Heart Association.
New-look TAVR valve shows early promise in patients with severe AS
One-year data presented at SCAI's annual meeting suggest interventional cardiologists could soon have a new way to treat severe aortic stenosis.
TAVR linked to lower stroke risk than SAVR in patients with AS and cardiogenic shock
TAVR is also associated with a lower risk of acute kidney injury in this patient population. In-hospital mortality rates, however, are similar between the two treatment options.

TAVR in low-risk patients holds steady at 2 years

Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery in low-risk patients with severe aortic stenosis, based on two-year results presented May 19 at EuroPCR in Paris.

May 19, 2015

Boston Scientific receives CE Mark for the new 25 mm Lotus Valve System

Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European commercial launch of its new 25 mm Lotus Transcatheter Aortic Valve Implantation (TAVI) System, complementing the currently available 23 mm and 27 mm valve sizes.

July 16, 2014

Boston Scientific Lotus Valve System demonstrates strong performance and safety profile at six months

Further validating its advanced transcatheter aortic valve implantation (TAVI) technology, the Boston Scientific Corporation Lotus Valve System continued to demonstrate impressive performance at six months, according to new data presented at EuroPCR 2014 in Paris.

May 22, 2014

Medtronic CoreValve System demonstrates positive clinical performance at two years in 'real world' ADVANCE study

Medtronic, Inc. today revealed new data showing that patients treated with the CoreValve System experienced positive clinical outcomes in the rigorous "real world" Medtronic CoreValve ADVANCE Study. Presented at EuroPCR 2014, the transcatheter aortic valve implantation (TAVI) study revealed low rates of mortality and stroke, and showed exceptional valve performance through two years.

May 22, 2014

Henry Ford Hospital pioneers new cardiac approach

Doctors at Henry Ford Hospital have created a new route to the heart to implant an artificial heart valve by temporarily connecting major blood vessels that do not normally intersect.

August 14, 2013

EuroPCR: SOURCE Registry one-year mortality rates inform TAVI operators

Martyn Thomas, MD, director of cardiothoracic services, Guys and St. Thomas' NHS Foundation Trust in London, reported Tuesday on the one-year mortality rates with transcatheter heart valve implantations with the Sapien valve (Edwards Lifesciences) using either a transfemoral or transapical approach, based on results of 1,038 high-risk patients assessed in the SOURCE Registry at EuroPCR in Paris. Slides

May 27, 2010

Around the web

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

TAVR

TAVR, SAVR linked to comparable long-term outcomes, new meta-analysis confirms

Updated balloon-expandable TAVR valve from Edwards outperforming its predecessors

Moderate aortic stenosis linked to heightened risk of death—should TAVR, surgery be considered?

New-look TAVR valve shows early promise in patients with severe AS

TAVR linked to lower stroke risk than SAVR in patients with AS and cardiogenic shock

Around the web